JP2019509330A - アルファアドレナリン作動薬の組成物および使用 - Google Patents

アルファアドレナリン作動薬の組成物および使用 Download PDF

Info

Publication number
JP2019509330A
JP2019509330A JP2018558113A JP2018558113A JP2019509330A JP 2019509330 A JP2019509330 A JP 2019509330A JP 2018558113 A JP2018558113 A JP 2018558113A JP 2018558113 A JP2018558113 A JP 2018558113A JP 2019509330 A JP2019509330 A JP 2019509330A
Authority
JP
Japan
Prior art keywords
alpha
adrenergic
adrenergic agonist
composition according
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2018558113A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019509330A5 (enExample
Inventor
フランク リットバック
フランク リットバック
ホウマン ヘマチ
ホウマン ヘマチ
Original Assignee
レベーション ファーマ リミテッド
レベーション ファーマ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by レベーション ファーマ リミテッド, レベーション ファーマ リミテッド filed Critical レベーション ファーマ リミテッド
Publication of JP2019509330A publication Critical patent/JP2019509330A/ja
Publication of JP2019509330A5 publication Critical patent/JP2019509330A5/ja
Priority to JP2022010224A priority Critical patent/JP2022058765A/ja
Priority to JP2024025657A priority patent/JP2024057010A/ja
Priority to JP2025162838A priority patent/JP2026001122A/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A61K8/4946—Imidazoles or their condensed derivatives, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q1/00—Make-up preparations; Body powders; Preparations for removing make-up
    • A61Q1/02—Preparations containing skin colorants, e.g. pigments
    • A61Q1/10—Preparations containing skin colorants, e.g. pigments for eyes, e.g. eyeliner, mascara
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Birds (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
JP2018558113A 2016-01-26 2017-01-26 アルファアドレナリン作動薬の組成物および使用 Withdrawn JP2019509330A (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2022010224A JP2022058765A (ja) 2016-01-26 2022-01-26 アルファアドレナリン作動薬の組成物および使用
JP2024025657A JP2024057010A (ja) 2016-01-26 2024-02-22 アルファアドレナリン作動薬の組成物および使用
JP2025162838A JP2026001122A (ja) 2016-01-26 2025-09-30 アルファアドレナリン作動薬の組成物および使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662287391P 2016-01-26 2016-01-26
US62/287,391 2016-01-26
PCT/US2017/015181 WO2017132410A1 (en) 2016-01-26 2017-01-26 Compositions and uses of alpha-adrenergic agents

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022010224A Division JP2022058765A (ja) 2016-01-26 2022-01-26 アルファアドレナリン作動薬の組成物および使用

Publications (2)

Publication Number Publication Date
JP2019509330A true JP2019509330A (ja) 2019-04-04
JP2019509330A5 JP2019509330A5 (enExample) 2020-03-05

Family

ID=59398678

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2018558113A Withdrawn JP2019509330A (ja) 2016-01-26 2017-01-26 アルファアドレナリン作動薬の組成物および使用
JP2022010224A Pending JP2022058765A (ja) 2016-01-26 2022-01-26 アルファアドレナリン作動薬の組成物および使用
JP2024025657A Pending JP2024057010A (ja) 2016-01-26 2024-02-22 アルファアドレナリン作動薬の組成物および使用
JP2025162838A Pending JP2026001122A (ja) 2016-01-26 2025-09-30 アルファアドレナリン作動薬の組成物および使用

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2022010224A Pending JP2022058765A (ja) 2016-01-26 2022-01-26 アルファアドレナリン作動薬の組成物および使用
JP2024025657A Pending JP2024057010A (ja) 2016-01-26 2024-02-22 アルファアドレナリン作動薬の組成物および使用
JP2025162838A Pending JP2026001122A (ja) 2016-01-26 2025-09-30 アルファアドレナリン作動薬の組成物および使用

Country Status (6)

Country Link
US (5) US10828252B2 (enExample)
EP (1) EP3407976A4 (enExample)
JP (4) JP2019509330A (enExample)
CN (2) CN115006537A (enExample)
AU (3) AU2017211793B2 (enExample)
WO (1) WO2017132410A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120225918A1 (en) 2011-03-03 2012-09-06 Voom, Llc Compositions and Methods for Non-Surgical Treatment of Ptosis
CN115006537A (zh) 2016-01-26 2022-09-06 利维申制药有限公司 α-肾上腺素能药剂的组合物和用途
US11007144B2 (en) 2016-11-15 2021-05-18 Klaria Pharma Holding Ab Pharmaceutical formulation
EP3595515A4 (en) 2017-03-14 2020-12-30 University of Connecticut BIODEGRADABLE PRESSURE SENSOR
GB201709141D0 (en) 2017-06-08 2017-07-26 Klaria Pharma Holding Ab Pharmaceutical formulation
KR20250099416A (ko) 2018-03-02 2025-07-01 퀀텀사이트, 인크. 조직으로부터 관심 영역의 단리 및 발현 분석을 위한 방법, 조성물, 및 장치
GB201808462D0 (en) 2018-05-23 2018-07-11 Klaria Pharma Holding Ab Pharmaceutical formulation
US20220025129A1 (en) * 2018-11-15 2022-01-27 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Lactide containing polyester-polyethylene glycol triblock thermoresponsive copolymers
US11826495B2 (en) 2019-03-01 2023-11-28 University Of Connecticut Biodegradable piezoelectric ultrasonic transducer system
US10814001B1 (en) 2019-05-06 2020-10-27 Rvl Pharmaceuticals, Inc. Oxymetazoline compositions
WO2021183626A1 (en) 2020-03-10 2021-09-16 University Of Connecticut Therapeutic bandage
US12491290B2 (en) 2020-06-08 2025-12-09 University Of Connecticut Biodegradable piezoelectric composite materials
CN112791033A (zh) * 2020-12-30 2021-05-14 广东蕾琪化妆品有限公司 一种新型眼影及其制备方法
US20240225978A1 (en) * 2021-01-23 2024-07-11 Christine Lynn Bokman Methods and compositions for pharmacological treatment of blepharoptosis
CN113149022B (zh) * 2021-04-30 2022-07-22 南昌大学 一种二氧化硅@硅酸钙中空纳米球及其制备方法和应用
US11779553B1 (en) 2022-11-28 2023-10-10 Atif B. D. Collins Methods and devices for treatment of eyelid ptosis
CN117122575A (zh) * 2023-10-16 2023-11-28 迪沙药业集团有限公司 一种硫酸氨基葡萄糖泡腾片药用组合物及制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011503061A (ja) * 2007-11-08 2011-01-27 アーシエックス セラピューティックス， インコーポレイテッド 浸透圧活性剤及び血管収縮剤を含む眼けん腫脹の治療及び防止のための組成物
US20110104206A1 (en) * 2009-10-30 2011-05-05 Intratus, Inc. Methods and compositions for sustained delivery of drugs
US20120058056A1 (en) * 2009-04-09 2012-03-08 University Of Medicine And Dentistry Of New Jersey Treatment of cutaneous hemangioma

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2784127A (en) 1954-06-02 1957-03-05 Eastman Kodak Co Plasticized monomeric adhesive compositions and articles prepared therefrom
US3993073A (en) 1969-04-01 1976-11-23 Alza Corporation Novel drug delivery device
US3598122A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US4069307A (en) 1970-10-01 1978-01-17 Alza Corporation Drug-delivery device comprising certain polymeric materials for controlled release of drug
US3731683A (en) 1971-06-04 1973-05-08 Alza Corp Bandage for the controlled metering of topical drugs to the skin
US3742951A (en) 1971-08-09 1973-07-03 Alza Corp Bandage for controlled release of vasodilators
US3996934A (en) 1971-08-09 1976-12-14 Alza Corporation Medical bandage
BE795384A (fr) 1972-02-14 1973-08-13 Ici Ltd Pansements
US3921636A (en) 1973-01-15 1975-11-25 Alza Corp Novel drug delivery device
US3993072A (en) 1974-08-28 1976-11-23 Alza Corporation Microporous drug delivery device
US3972995A (en) 1975-04-14 1976-08-03 American Home Products Corporation Dosage form
US4077407A (en) 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
US4031894A (en) 1975-12-08 1977-06-28 Alza Corporation Bandage for transdermally administering scopolamine to prevent nausea
US4060084A (en) 1976-09-07 1977-11-29 Alza Corporation Method and therapeutic system for providing chemotherapy transdermally
US4201211A (en) 1977-07-12 1980-05-06 Alza Corporation Therapeutic system for administering clonidine transdermally
JPS5562012A (en) 1978-11-06 1980-05-10 Teijin Ltd Slow-releasing preparation
US4230105A (en) 1978-11-13 1980-10-28 Merck & Co., Inc. Transdermal delivery of drugs
US4291015A (en) 1979-08-14 1981-09-22 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing a vasodilator
US4444933A (en) 1982-12-02 1984-04-24 Borden, Inc. Adhesive cyanoacrylate compositions with reduced adhesion to skin
US4757128A (en) 1986-08-01 1988-07-12 Massachusetts Institute Of Technology High molecular weight polyanhydride and preparation thereof
US5312325A (en) 1987-05-28 1994-05-17 Drug Delivery Systems Inc Pulsating transdermal drug delivery system
US5462990A (en) 1990-10-15 1995-10-31 Board Of Regents, The University Of Texas System Multifunctional organic polymers
US5633009A (en) 1990-11-28 1997-05-27 Sano Corporation Transdermal administration of azapirones
DE69329594T2 (de) 1992-02-28 2001-05-31 Board Of Regents, The University Of Texas System Photopolymerinierbare, biologisch abbaubare hydrogele als gewebekontaktmaterialien und trägerstoffe für kontrollierte freisetzung
US5665378A (en) 1994-09-30 1997-09-09 Davis; Roosevelt Transdermal therapeutic formulation
US5654381A (en) 1995-06-16 1997-08-05 Massachusetts Institute Of Technology Functionalized polyester graft copolymers
US6929801B2 (en) 1996-02-19 2005-08-16 Acrux Dds Pty Ltd Transdermal delivery of antiparkinson agents
US6923983B2 (en) 1996-02-19 2005-08-02 Acrux Dds Pty Ltd Transdermal delivery of hormones
US5628863A (en) 1996-06-12 1997-05-13 Lee; Shu-Ken Pouch producing machine
US5869090A (en) 1998-01-20 1999-02-09 Rosenbaum; Jerry Transdermal delivery of dehydroepiandrosterone
US6503231B1 (en) 1998-06-10 2003-01-07 Georgia Tech Research Corporation Microneedle device for transport of molecules across tissue
US6946144B1 (en) 1998-07-08 2005-09-20 Oryxe Transdermal delivery system
US6611707B1 (en) 1999-06-04 2003-08-26 Georgia Tech Research Corporation Microneedle drug delivery device
US6312612B1 (en) 1999-06-09 2001-11-06 The Procter & Gamble Company Apparatus and method for manufacturing an intracutaneous microneedle array
US6945952B2 (en) 2002-06-25 2005-09-20 Theraject, Inc. Solid solution perforator for drug delivery and other applications
KR20050092429A (ko) * 2003-01-22 2005-09-21 니찌방 가부시기가이샤 안질환 치료용 경피 흡수형 제제, 그 사용, 및 안질환치료약의 눈의 국소 조직으로의 이행 방법
US7776915B2 (en) * 2005-03-24 2010-08-17 Tracie Martyn International, Llc Topical formulations and methods of use
US20090136598A1 (en) * 2006-04-26 2009-05-28 Aciex, Inc. Compositions for the Treatment and Prevention of Eyelid Swelling
US8685439B2 (en) * 2006-04-26 2014-04-01 Aciex Therapeutics, Inc. Method for the treatment and prevention of eyelid swelling
CA2695731C (en) 2007-08-06 2018-04-03 Transderm, Inc. Microneedle arrays formed from polymer films
DK2645993T3 (en) 2010-12-03 2017-02-13 Allergan Inc Pharmaceutical cream compositions comprising oxymetazoline
US20120225918A1 (en) * 2011-03-03 2012-09-06 Voom, Llc Compositions and Methods for Non-Surgical Treatment of Ptosis
CA2841632A1 (en) 2011-07-14 2013-01-17 Allergan, Inc. Gel compositions of oxymetazoline and methods of use
US20130035338A1 (en) * 2011-08-05 2013-02-07 Gordon Tang Eyelid treatment
US10272233B2 (en) 2012-03-16 2019-04-30 National University Of Singapore Method to fabricate polymeric microneedles
KR20150016356A (ko) 2012-06-29 2015-02-11 이엘씨 매니지먼트 엘엘씨 하나 이상의 캡슐화된 화장 성분을 포함하는 용해가능한 미세바늘
CA2951725C (en) 2014-06-11 2022-06-07 Allergan, Inc. Stabilized oxymetazoline formulations and their uses
US20190000808A1 (en) 2015-07-13 2019-01-03 Allergan, Inc. Composition and methods for the treatment of blephopharoptosis
CN115006537A (zh) 2016-01-26 2022-09-06 利维申制药有限公司 α-肾上腺素能药剂的组合物和用途

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011503061A (ja) * 2007-11-08 2011-01-27 アーシエックス セラピューティックス， インコーポレイテッド 浸透圧活性剤及び血管収縮剤を含む眼けん腫脹の治療及び防止のための組成物
US20120058056A1 (en) * 2009-04-09 2012-03-08 University Of Medicine And Dentistry Of New Jersey Treatment of cutaneous hemangioma
US20110104206A1 (en) * 2009-10-30 2011-05-05 Intratus, Inc. Methods and compositions for sustained delivery of drugs

Also Published As

Publication number Publication date
AU2022257242A1 (en) 2022-11-24
CA3012660A1 (en) 2017-08-03
EP3407976A4 (en) 2019-07-17
US10828252B2 (en) 2020-11-10
AU2017211793B2 (en) 2022-11-24
US20210259956A1 (en) 2021-08-26
JP2022058765A (ja) 2022-04-12
CN108883308A (zh) 2018-11-23
EP3407976A1 (en) 2018-12-05
WO2017132410A1 (en) 2017-08-03
US20230181455A1 (en) 2023-06-15
US11311476B2 (en) 2022-04-26
US12357561B2 (en) 2025-07-15
AU2017211793A1 (en) 2018-08-02
US20210259955A1 (en) 2021-08-26
AU2024200121A1 (en) 2024-01-25
CN115006537A (zh) 2022-09-06
AU2024200121B2 (en) 2025-11-13
US20180325806A1 (en) 2018-11-15
JP2024057010A (ja) 2024-04-23
JP2026001122A (ja) 2026-01-06
US11491104B2 (en) 2022-11-08
US20260034050A1 (en) 2026-02-05

Similar Documents

Publication Publication Date Title
AU2024200121B2 (en) Compositions and uses of alpha-adrenergic agents
DK2767292T3 (en) RENEWABLE local anesthetic COMPOSITION CONTAINING SAIB
JP4944896B2 (ja) 低減された非毒素タンパク質を含むボツリヌス毒素の局所適用及び経皮送達のための組成物及び方法
JP2015042658A (ja) 局所使用のためのビタミンｋ類似体製剤
JP2002308728A (ja) 高分子ナノ粒子を用いた経皮吸収剤及びこれを含有する外用剤
US20220096371A1 (en) Biodegradable microneedle system with sustained release
JP2021529811A (ja) 局所用デトミジン製剤
ES2596720A1 (es) Composiciones para uso tópico
WO2017117268A1 (en) Topical therapeutic formulations containing a calcium channel blocker, superoxide dismutase and emu oil
JP2024507266A (ja) ヒドロゲル組成物、ならびに放射線によって引き起こされる皮膚損傷の予防および／または処置におけるその使用
Shalaby et al. Advantages and therapeutic applications of different semisolids as vehicles for nano-based systems
CA3012660C (en) Composition of alpha-adrenergic agents for the treatment of ptosis
HK40079495A (en) Compositions and uses of alpha-adrenergic agents
CA3248300A1 (en) COMPOSITION BASED ON HYDROGEL AND A LONGER-RELEASE LOCAL ANESTHETIC
JP2005524642A (ja) ハロフジノンおよびその他のキナゾリノン誘導体の安定化医薬組成物
US20110319811A1 (en) Combination therapy with cryosurgery and low dosage strength imiquimod to treat actinic keratosis
JP2024507011A (ja) エマルション組成物、ならびに放射線によって引き起こされる皮膚損傷の予防および／または処置におけるその使用
Tran et al. Application of nanostructured lipid carriers for transdermal drug delivery
WO2025111378A1 (en) Semi-solid formulations of deferoxamine for the treatment of radiation therapy burns
JPWO2020111248A1 (ja) ワクチン製剤
Dahal Assessment of the Percutaneous Absorption of ABH PLO Gel Across Porcine Ear Skin
Abdelzahraa Republic of Iraq
Antunes State-Of-Art on Gel Technologies for Transdermal Delivery of Bacitracin

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180905

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200124

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200124

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210115

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210120

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210416

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210719

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210927

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220126

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220126

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20220207

C27A Decision to dismiss

Free format text: JAPANESE INTERMEDIATE CODE: C2711

Effective date: 20220328

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20220331